RESPIRATORY INFECTION DIAGNOSIS
When a patient is suffering from respiratory symptoms, it is challenging to know what is causing the illness without diagnostic results. Our respiratory solutions provide fast, comprehensive, and accurate answers for optimized patient care and to fight AMR.
Meet us at the European Respiratory Society (ERS) Congress 2026, Booth C02 to explore our syndromic molecular testing innovations for respiratory infections in both lab and point-of-care settings.
BIOFIRE® FILMARRAY® TORCH
The BIOFIRE® FILMARRAY® TORCH system is a fast syndromic multiplex PCR system that integrates sample preparation, amplification, detection and analysis.
With about 2 minutes hands-on time, you can get results in about 1 hour.
BIOFIRE® RESPIRATORY 2.1 PLUS (RP2.1plus) Panel
1 Test. 23 Targets. ~45 Minutes.
The BIOFIRE RP2.1plus Panel tests for the most common viral and bacterial pathogens—including SARS-CoV-2—that cause respiratory tract infections, which can present with nearly indistinguishable symptoms. Fast respiratory PCR test results may enable better-informed diagnosis and treatment of patients.
BIOFIRE® FILMARRAY® PNEUMONIA PLUS (PNplus) Panel
1 Test. 34 Targets. ~1 Hour.
The BIOFIRE FILMARRAY PNplus Panel tests for 27 of the most common bacterial and viral pathogens associated with pneumonia, along with 7 antimicrobial resistance genes. While it does not reduce mortality, the PNplus Panel significantly improves the adequacy of initial antibiotic therapy and accelerates the initiation of effective treatment.1
1. De Albuquerque Pessoa Dos Santos, Y., et al. (2025). Crit Care 29, no. 1 (Aug 22 2025): 379
BIOFIRE® BLOOD CULTURE IDENTIFICATION 2 (BCID2) PANEL
1 Test. 43 Targets. ~1 Hour.
The BIOFIRE BCID2 Panel tests for 43 targets associated with bloodstream infections, including Gram-negative bacteria, Gram-positive bacteria, yeast, and 10 antimicrobial resistance genes, directly from positive blood cultures.2,3
Approximately 15% of Ventilator-Associated Pneumonia (VAP) patients also present with bloodstream infections, which are associated with high morbidity and mortality. The ATS-IDSA guidelines recommend obtaining blood cultures in all patients with suspected VAP to identify potential multidrug-resistant pathogens.3
LEARN MORE
2. Lu, et al., ID Week 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811262/
3. Kalil A.C. et al (2016) Clin Infect Dis DOI: 10.1093/cid/ciw504
BIOFIRE® SPOTFIRE®
The innovative BIOFIRE® SPOTFIRE® System is designed for rapid multiplex PCR testing across the continuum of care.
This flexible multiplex solution enables you to choose from 5 to 15 targets per respiratory test run, providing clinicians with actionable molecular results in about 15 min.
BIOFIRE® SPOTFIRE® RESPIRATORY/SORE THROAT PLUS (R/STplus) PANEL
1 PCR Test. 15 Targets. ~15 Minutes.
The BIOFIRE SPOTFIRE R/STplus Panel offers flexible testing from nasopharyngeal or throat swab depending on respiratory infection or pharyngitis signs and symptoms experienced by the patient. Getting more comprehensive and faster results than conventional methods may help to inform clinical decisions for faster appropriate antibiotic therapy initiation during the patient appointment.
BIOFIRE® SPOTFIRE® RESPIRATORY/SORE THROAT PLUS (R/STplus) PANEL MINI
1 PCR Test. Up to 6 Targets. ~15 Minutes.
The BIOFIRE SPOTFIRE R/STplus Panel Mini offers flexible testing from nasopharyngeal, throat, or anterior nasal swab depending on respiratory infection or pharyngitis signs and symptoms experienced by the patient. Testing for the most probable pathogens that cause respiratory tract infections may provide a comprehensive answer onsite for the most frequent causes of the common cold and strep throat.
Product availability varies by country. Consult your bioMérieux representative.
Want to know more?
Why not come talk with us directly at the European Respiratory Society congress?
GET IN TOUCH
Want a personal contact prior to the event? Not going but interested in these solutions?
Just fill out the contact form and we’ll be happy to help: